ArticlePLoS pathogens2025
Antibiotic-induced morphological changes enhance phage predation.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Chloramphenicol and tetracycline synergize with bacteriophage SeKF_13 to inactivate antimicrobial-resistantMicrobiology spectrum · 2026Article
- Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Phage-antibiotic synergy attenuatesFrontiers in cellular and infection microbiology · 2026Article
- Management of Diabetic Foot Infections Using Phage Therapy.Infection and drug resistance · 2026Review
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Due to the high public health risk posed by antibioresistance, phage therapy - the use of bacteriophages as antibacterial agents - is experiencing renewed interest. As the combined administration of antibiotics and phages is a common practice in compassionate treatments, our research focuses on the effects of antibiotics on phage predation, which may be of crucial importance for phage therapeutic applications. A distinctive manifestation of phage infection in solid media is the appearance of lysis plaques, corresponding to the circular thinning of a bacterial lawn. During plaque formation, successive cycles of phage replication take place from a single point of infection and spread radially in a lawn of immobilized bacterial hosts. Many factors affect plaque size, such as the composition and the reticulation of the propagation matrix, the characteristics of the phage, but also parameters related to the physiology of the bacterial host. It has also been known for decades that some antibiotics enable phages to spread more rapidly, resulting in better bacterial eradication. This phenomenon, called Phage-Antibiotic Synergy (PAS), is evidenced by larger lysis plaques on solid media. Our previous experimental work has focused on the phage characteristics and pointed to enhanced adsorption as a key factor leading to more efficient predation. However, since sublethal antibiotic concentrations can drastically affect bacterial physiology - for instance halting cell division in the case of ciprofloxacin or ceftazidime - and since plaque formation is strongly influenced by host growth dynamics, a comprehensive model integrating both the host growth and phage infection parameters is required to investigate PAS. We characterized the epidemics of two different phages (T5 and T7) during E. coli MG1655 infection on semi-solid media in the presence of sublethal antibiotic concentrations that affect (or not) cell morphology in different ways (cell filamentation or cell bloating). We observed that in these conditions lysis plaque enlargement is linked to the host's morphological changes. We conclude this work with a mathematical model that captures such observations and explains the increase in plaque size observed in the presence of antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.